1dcy: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
New page: left|200px<br /> <applet load="1dcy" size="450" color="white" frame="true" align="right" spinBox="true" caption="1dcy, resolution 2.70Å" /> '''CRYSTAL STRUCTURE O...
 
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:1dcy.gif|left|200px]]<br />
[[Image:1dcy.gif|left|200px]]<br /><applet load="1dcy" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="1dcy" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="1dcy, resolution 2.70&Aring;" />
caption="1dcy, resolution 2.70&Aring;" />
'''CRYSTAL STRUCTURE OF HUMAN S-PLA2 IN COMPLEX WITH INDOLE 3 ACTIVE SITE INHIBITOR'''<br />
'''CRYSTAL STRUCTURE OF HUMAN S-PLA2 IN COMPLEX WITH INDOLE 3 ACTIVE SITE INHIBITOR'''<br />


==Overview==
==Overview==
A lead compound obtained from a high volume human non-pancreatic secretory, phospholipase A2 (hnps-PLA2) screen has been developed into a potent, inhibitor using detailed structural knowledge of inhibitor binding to the, enzyme active site. Four crystal structures of hnps-PLA2 complexed with a, series of increasingly potent indole inhibitors were determined and used, as the structural basis for both understanding this binding and providing, valuable insights for further development. The application of, structure-based drug design has made possible improvements in the binding, of this screening lead to the enzyme by nearly three orders of magnitude., Furthermore, the optimized structure (LY311727) displayed 1,500-fold, selectivity when assayed against porcine pancreatic s-PLA2.
A lead compound obtained from a high volume human non-pancreatic secretory phospholipase A2 (hnps-PLA2) screen has been developed into a potent inhibitor using detailed structural knowledge of inhibitor binding to the enzyme active site. Four crystal structures of hnps-PLA2 complexed with a series of increasingly potent indole inhibitors were determined and used as the structural basis for both understanding this binding and providing valuable insights for further development. The application of structure-based drug design has made possible improvements in the binding of this screening lead to the enzyme by nearly three orders of magnitude. Furthermore, the optimized structure (LY311727) displayed 1,500-fold selectivity when assayed against porcine pancreatic s-PLA2.


==Disease==
==Disease==
Line 11: Line 10:


==About this Structure==
==About this Structure==
1DCY is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with CA and I3N as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Phospholipase_A(2) Phospholipase A(2)], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.1.1.4 3.1.1.4] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1DCY OCA].  
1DCY is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=CA:'>CA</scene> and <scene name='pdbligand=I3N:'>I3N</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Phospholipase_A(2) Phospholipase A(2)], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.1.1.4 3.1.1.4] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1DCY OCA].  


==Reference==
==Reference==
Line 18: Line 17:
[[Category: Phospholipase A(2)]]
[[Category: Phospholipase A(2)]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Chirgadze, N.Y.]]
[[Category: Chirgadze, N Y.]]
[[Category: Schevitz, R.W.]]
[[Category: Schevitz, R W.]]
[[Category: Wery, J.P.]]
[[Category: Wery, J P.]]
[[Category: CA]]
[[Category: CA]]
[[Category: I3N]]
[[Category: I3N]]
Line 26: Line 25:
[[Category: s-pla2; structure-based drug design]]
[[Category: s-pla2; structure-based drug design]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 16:31:03 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 12:15:23 2008''